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Introduction
Important advances in human health have 
come from the recognition of health hazards 
and the development of policy actions to 
address them (Brownson et al. 2009; Espina 
et al. 2013; Samet 2000). Government and 
non governmental organizations use expert 
panels to review the scientific literature 
and to assess its relevance to public health 
policies. Scientific experts are charged with 
reviewing the quality and quantity of the 
scientific evidence and providing scientific 
interpretations of the evidence that underpin 
a range of health policy decisions.
The IARC Monographs on the Evaluation 
of Carcinogenic Risks to Humans of the 
International Agency for Research on Cancer 
(IARC) are a prominent example of such 
an expert review process. The goal of the 
Monograph Programme is to assess carcino-
genic hazards from occupational, environ-
mental, and lifestyle exposures and agents, 
thus providing an essential step in the societal 
decision-making process to identify and 
then control carcinogenic hazards. For these 
evaluations, IARC assembles groups of scien-
tists with a range of relevant scientific exper-
tise (called “Working Groups”) to review and 
assess the quality and strength of evidence 
from informative publications and perform a 
hazard evaluation to assess the likelihood that 
the agents of concern pose a cancer hazard 
to humans (Tomatis 1976). IARC has used 
this approach for four decades, since the first 
Monograph in 1972 (IARC 1972). Although 
widely accepted inter nationally, there 
have been criticisms of the classification of 
particular agents in the past, and more recent 
criticisms have been directed at the general 
approach adopted by IARC for such evalua-
tions (Boffetta et al. 2009; Epidemiology 
Monitor 2012; Ioannidis 2005; Kabat 2012; 
McLaughlin et al. 2010, 2011).
The Monographs are widely used and 
referenced by governments, organizations, 
and the public around the world; therefore, 
it is critical that Working Group conclusions 
be clear and transparent. In addition to the 
actual evaluation, a major contribution of 
the Monographs is the assembly of relevant 
literature and its dissemination to the public. 
We recognize that no system of evaluation is 
perfect. It is important to foster continuing 
improvement of the methods used by IARC 
and other bodies that review scientific 
evidence. The IARC process itself has been 
modified from time to time (e.g., addition of 
specific evaluation of mechanistic data and 
greater use of formal meta-analyses and data-
pooling approaches). Indeed, as recently as 
April 2014, the IARC Monographs program 
has been a subject of a review by the Advisory 
Group to recommend priorities for IARC 
Monographs during 2015–2019 (Straif 
et al. 2014). The Advisory Group has made 
a number of recommendations on further 
improvements in the Monographs process 
specifically related to conflict of interest, 
transparency, and the use of the systematic 
review procedures in data gathering and 
evaluation. Thus, possible changes to the 
process are periodically considered by IARC 
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governing groups (Scientific Council and 
Governing Council) and Advisory Groups.
Here, we focus on current IARC processes 
and practices because these have been the 
focus of recent criticisms. The authors of this 
Commentary are scientists from a wide range 
of disciplines who are involved in designing 
and conducting studies that provide data 
used in hazard evaluations, such as those 
performed by IARC. Many (but not all) of us 
have served on IARC Monograph Working 
Groups, but none are current IARC staff. We 
first discuss the history of IARC, and describe 
how the IARC evaluations are performed in 
order to foster evidence-based policy. We 
then describe why unbiased evalua tions, 
based on the evidence and free of conflicts 
of interest, are necessary for public health 
decision making. Finally, we discuss the 
recent criticisms of the IARC approach.
The IARC Monographs
History of the IARC Monographs. Shortly 
after IARC’s establishment, its parent entity, 
the World Health Organization (WHO), 
asked IARC to prepare a list of agents known 
to cause cancer in humans. IARC recognized 
the need for a systematic process to determine 
which agents should be listed. Such a process 
was launched in 1972 by Lorenzo Tomatis, 
then Chief of the Division of Carcinogenicity 
of IARC (Tomatis 1976). IARC is funded by 
the governments of 24 countries that have 
decided to become members, in addition to 
competitive grants from funding agencies. 
The IARC Monograph Programme is 
mainly funded by the U.S. National Cancer 
Institute through a renewable grant subject 
to peer review of the program. Other sources 
of external funding have included the 
European Commission Directorate-General 
of Employment, Social Affairs and Equal 
Opportunities; the U.S. National Institute of 
Environmental Health Sciences; and the U.S. 
Environmental Protection Agency.
The IARC process antedates current 
systematic review methods, but anticipated 
some of them, for example, with regard to 
transparent literature identification. In the 
IARC process, agents are assessed for carcino-
genic hazard and assigned to one of five cate-
gories, ranging from carcinogenic to humans 
to probably not carcinogenic to humans 
(Appendix 1). The classification categories are 
described in the preamble to the Monographs 
(IARC 2006). Carcinogenic hazard identifica-
tion refers to an assessment of whether an agent 
causes cancer. Hazard identification does not 
predict the magnitude of cancer risks under 
specific conditions; this can be determined only 
with appropriate exposure–response informa-
tion (National Research Council 2009).
The IARC Monograph process. The process 
for the preparation of an IARC Monograph 
is clearly described in the Preamble, which is 
published as part of each Monograph (e.g., 
IARC 2014a). It starts with the nomination 
of candidate agents. Nominations come from 
national regulatory agencies, scientists, and 
stakeholders, including public health profes-
sionals, experts in environmental or occu-
pational hygiene, industry representatives, 
and private citizens. It is important to note 
that anyone (including private citizens) can 
participate in the nomination process. The 
Monograph Programme convenes meetings 
of special Advisory Groups (composed of 
external scientists that possess a broad range 
of relevant professional skills) to review agents 
nominated for evaluation and to suggest 
IARC priorities for such reviews (Ward et al. 
2010). Announcements of a review are made 
on the IARC website (http://monographs.iarc.
fr/ENG/Meetings/). For example, in 2013 
IARC sought nominations for agents to be 
evaluated in 2015–2019 (IARC 2014b). An 
Advisory Group reviewed the nominated 
agents and exposures, added several new ones, 
and discussed the priorities for each.
The IARC staff makes the final selection 
of agents for review by taking into account 
the prevalence and intensity of exposure (of 
both occupational groups and the general 
population) and availability of sufficient 
literature for an evaluation of carcinogenicity, 
as well as advice from the Advisory Groups. 
The large majority of evaluations concern 
specific compounds, but there are also mono-
graphs on various occupations or industries, 
for example, aluminum production, insecti-
cide applicators, firefighters, manufacture of 
leather goods, leather tanning and processing, 
welding, painters, petroleum refining, and 
pulp and paper manufacturing. Some indi-
vidual exposures that occur in these settings 
have also been evaluated.
The next step is the selection of members 
of the Working Group (WG). IARC staff 
review the literature to identify Working 
Group candidates and specialists in relevant 
areas of expertise; they also seek names 
of possible candidates from the scientific 
community and advisory groups. The list of 
potential members, including disclosure of 
relevant conflicts of interest, is posted on the 
IARC website (http://monographs.iarc.fr/
ENG/Meetings/) before the WG is convened, 
and anyone can send comments. Members 
are typically scientists who have conducted 
research relevant to the agent under review, 
but not necessarily on the specific agent. 
Selection procedures are evaluated yearly by 
the Scientific and the Governing Councils. 
The IARC Section of Monographs also 
has an external Advisory Board, made up 
of independent scientists, that periodically 
peer reviews its activities. In addition to 
Working Group members, invited specialists, 
representatives of health agencies, stakeholder 
observers, and the IARC Secretariat also 
attend meetings.
The responsibility of the Working 
Group is to review the literature before the 
Monograph meeting, discuss the literature 
at the meeting, and then classify whether an 
agent is carcinogenic, probably carcinogenic, 
possibly carcinogenic, not classifiable, or 
probably not carcinogenic to humans (see 
Appendix 1). Working Group members 
are also responsible for writing the IARC 
Monograph, which must both review the 
literature and explain why the Working 
Group came to their specific conclusions.
The procedures used to evaluate the scien-
tific evidence are described in the Preamble 
to the Monographs (IARC 2006). It is 
important to stress that only Working Group 
members conduct the actual evalua tion (Wild 
and Cogliano 2011; Wild and Straif 2011). 
IARC staff facilitate the evalua tion process and 
ensure that the procedures described in the 
Preamble are followed; however, they do not 
determine the outcomes.
IARC assessments of carcinogenicity 
are based on, and necessarily limited to, 
scientific evidence available at the time 
of the review. The evidence comes from 
epidemiologic studies, animal bioassays, 
pharmacokinetic/mechanistic experiments, 
and surveys of human exposure. The aim is 
to include all relevant papers on cancer in 
humans and experimental animals that have 
been published, or accepted for publication, 
in peer-reviewed scientific journals and also 
any publicly available government or agency 
documents that provide data on the circum-
stances and extent of human exposure. To 
that end, the search of the literature takes a 
comprehensive approach. Papers that are 
found not to provide useful evidence can be 
excluded later in the process. IARC staff first 
use previous IARC Monographs (if available), 
database searches using relevant text strings, 
and contact with investigators in the field to 
identify potentially relevant material. Thus, the 
initial assembly of the literature is performed 
by individuals who are not engaged in the 
actual evaluation. Working Group members 
are then assigned various writing tasks and 
are instructed to perform their own literature 
searches to identify any further papers that 
might have been missed. In addition, all of the 
papers assembled by IARC are made available 
to the full Working Group before they meet, 
and any member can recommend other papers 
not previously identified that they think should 
be considered. Finally, papers can be recom-
mended by stakeholder representatives before 
or during the Working Group meeting.
At the meeting of the Working Group, 
the assembled documents are reviewed and 
summarized by discipline-related subgroups.
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However, any member of the Working Group 
has access to all of the assembled literature. The 
summaries are distributed to all subgroups, and 
information from all disciplines is discussed in 
plenary sessions prior to assigning the agents to 
a specific carcino genicity category.
Because new findings continually emerge 
in the literature, agents are reconsidered when 
IARC and IARC Advisory Groups judge 
that there is sufficient additional information 
that might alter a previous evaluation. Thus, 
conclusions regarding human carcinogenicity 
of particular substances may change as new 
evidence becomes available. For some agents, 
this reevaluation has resulted in progres-
sion toward greater certainty regarding their 
human carcinogenicity, whereas for others 
the progress has been moved toward less 
certainty. Such movements are expected in 
an open, transparent, and evidence-based 
process. A comprehensive update of all 
Group 1 carcinogens was recently accom-
plished in Volume 100 A through F (http://
monographs.iarc.fr/ENG/Monographs/
PDFs/index.php).
Usually, several agents are evaluated in a 
single meeting lasting more than 1 week. After 
discussing the evidence fully, the Working 
Group members follow the published IARC 
procedures for combining information from 
epidemiologic studies and bioassays to arrive 
at a preliminary classification (IARC 2014a). 
Mechanistic data are then considered in order 
to determine whether they warrant a change 
from the preliminary classification. The 
Working Group then votes on the final deter-
mination. Many votes are unanimous, but on 
occasion some reviewers may favor a higher 
or lower ranking than the majority. When 
there is dissent, alternative interpretations 
and their underlying reasoning are sometimes 
reported in the rationale for the evaluation if 
the dissenters feel their point of view is not 
sufficiently addressed in the monograph.
Consideration of the totality of the 
evidence. IARC Working Groups make 
every effort to provide full and transparent 
documentation of what evidence was 
assembled, how it was evaluated, and which 
papers were most important for the hazard 
evaluation. Consequently, the monographs 
are often quite lengthy, containing many 
evidence tables [see, for example, the recent 
monograph on trichloroethylene (IARC 
2014c)]. Evaluations involve consideration 
of all of the known relevant evidence from 
epidemiologic, animal, pharmacokinetic/
mechanistic, and exposure studies to assess 
cancer hazard in humans. Information on 
human exposure is not formally graded as 
part of the overall assessment of carcinogenic 
hazard; however, these data make a critical 
contribution to the process by charac-
terizing the timing, duration, and levels of 
exposure in the population, and in evaluating 
the quality of the exposure assessment in 
epidemiologic studies.
Doubts and criticisms have sometimes 
been expressed about the relative weights 
attributed to evidence from individual disci-
plines to the assessment of cancer hazards to 
humans; however, each discipline provides 
important evidence toward the overall evalu-
ation of causality according to the Bradford 
Hill considerations (Hill 1965). Because the 
totality of the evidence is considered, defi-
ciencies in one discipline are often offset by 
strengths in another. For example, epidemio-
logic studies may focus on population-relevant 
exposures, whereas findings from animal 
experiments usually involve higher exposures 
but are less susceptible to confounding.
Long-term animal bioassays and mecha-
nistic studies provide critical information on 
the capacity of an agent to produce cancer 
in mammalian systems, including humans, 
and to contribute to decisions that would 
lead to better protection of human health. 
Bioassays are the backbone of regulatory 
science because they provide the opportu-
nity to rigorously evaluate potential hazards 
before there is widespread human exposure. 
Bioassays and mechanistic studies are some-
times criticized for employing exposure routes 
and doses that in most instances humans 
would not experience, although experimental 
dose categories sometimes approach exposure 
levels found in occupational situations. There 
is evidence that carcinogenicity in human and 
animal studies is often concordant, although 
data may differ as to the affected cancer site 
(Haseman 2000; Maronpot et al. 2004; 
Tomatis 2002). A major effort to evaluate 
the concordance between animal and human 
results is currently under way; two Working 
Groups were convened at IARC in 2012, and 
a systematic evaluation of the correspondence 
between human and animal data was under-
taken (a report is not yet publicly available). 
Criticisms of the IARC Process
IARC Monographs are widely used to 
identify potential carcinogenic hazards to 
humans and serve as reference documents 
summarizing the literature on many different 
agents. In recent years, however, individuals 
have criticized both the classification of indi-
vidual agents as well as the general evaluative 
approach (Boffetta et al. 2009; Epidemiology 
Monitor 2012; Kabat 2012; McLaughlin 
et al. 2010, 2011). We discuss four of these 
criticisms below.
Criticisms of epidemiology. Some of the 
criticisms of the IARC process have occurred 
in the context of more general criticisms 
of epidemiology as a science (Kabat 2008); 
these were discussed in detail by Blair et al. 
(2009). Potential methodological weaknesses 
for observational epidemiologic studies are 
well recognized and can be found in any 
epidemiologic textbook (Checkoway et al. 
2004; Rothman et al. 2008). Most studies 
are subject to one or more methodological 
limitations, but this does not necessarily 
invalidate their findings (Blair et al. 2009). 
In fact, the value of epidemiologic studies has 
been shown by the identification of a number 
of well-established human carcino gens, 
including tobacco, asbestos, benzene, hexa-
valent chromium, and some viruses, in 
multiple studies. Some critics also argue that 
small or non existent health risks are unjustifi-
ably highlighted and hyped by researchers who 
have a vested interest in continued research 
funding and the need to publish to benefit 
their careers (Boffetta et al. 2008; Kabat 
2008; McLaughlin et al. 2010, 2011; Taubes 
1995). However, such over stated results are 
unlikely to exert much of an influence in a 
Monograph because IARC evaluations are 
based on the totality of the evidence. The 
problem would have to occur in multiple 
studies, and the Working Group would have 
to be unable to identify it or be unwilling to 
weigh such studies appropriately. Incorrect 
positive conclusions regarding carcino genicity 
may also occur in reviews of multiple studies 
because of publication bias, which may 
selectively populate the literature only with 
“positive” findings. However, once a topic is 
recognized as scientifically important, reports 
on relevant studies will be published regardless 
of the findings, so publication bias is mainly a 
concern for newly arising issues. To evaluate 
the potential for publication bias, Working 
Groups consider whether stronger negative 
studies (both in terms of design and sample 
size) have emerged after publication of an 
initial cluster of smaller and/or weaker positive 
studies. Funnel plots help in the assessment 
of bias relating to sample size and publica-
tion bias (Borenstein et al. 2009). In contrast, 
there are no established statistical techniques 
to clearly characterize strength of design.
One of the distinctive features of epide-
miology is that criticism and self-criticism 
are firmly embedded in the discipline. A 
great deal of work has been done on devel-
oping methods for critical appraisal (Elwood 
2007) and for assessing the likely strength 
and direction of possible biases (Rothman 
et al. 2008). Epidemiologists and other 
members on Working Groups routinely use 
various approaches to assess possible bias in 
study design and analysis when weighing the 
strengths of different studies.
The issue of false positives. Epidemiology 
specifically has been criticized for a tendency 
to produce false-positive results (i.e., indi-
vidual study associations not borne out by 
the weight of the evidence) or to preferen-
tially report positive findings over negative 
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or inconclusive findings (i.e., publication 
bias) (Boffetta et al. 2008, 2009; Ioannidis 
2005; Kabat 2012; McLaughlin and Tarone 
2013). This criticism has been most often 
applied to potential false positives from 
individual studies, but it has been inferred 
that this problem may also apply to overall 
hazard evaluations, which use findings from 
multiple studies. We will consider each of 
these issues in turn.
False-positive findings may occur by 
chance, particularly when many combinations 
of exposures and health outcomes have been 
examined in a single study without strong 
prior expectations of association; this happens 
often, for example, in genome-wide associa-
tion studies where thousands of gene–disease 
associations are evaluated. Chance, of course, 
operates in all disciplines and in both obser-
vational and experimental studies. However, 
there are well-known statistical techniques 
to reduce the probability of declaring chance 
findings as “positive” (Rothman et al. 2008). 
Independent replication, however, is the most 
convincing way of checking for “chance” 
findings; hazard evaluations, such as those 
conducted by IARC Working Groups, rely 
heavily on reproducibility in independent 
studies and also interpret data following 
Bradford Hill principles (Hill 1965). 
False negatives are more difficult to 
address, and perhaps they occur more 
frequently than false positives because of low 
statistical power, non differential misclas-
sification of exposure and/or outcome, and 
incomplete follow-up, which tends to reduce 
the observed difference in risk between 
the exposed and non exposed populations 
(Ahlbom et al. 1990; Blair et al. 2009; 
Grandjean 2005; Rothman et al. 2008). A 
new positive association stimulates research, 
whereas studies finding no associations tend 
to stifle further work.
There are difficulties in conducting 
epidemiologic studies of agents that are rela-
tively “weak” carcinogens, or for stronger 
carcinogens where exposure is very low 
because bias and confounding can obscure 
weak positive associations (MacMahon et al. 
1981). In general, weak carcinogens and low 
levels of exposure result in a smaller “signal-
to-noise” ratio making the real signal more 
difficult to detect. Although the identifica-
tion of small relative risks to humans poses 
special challenges to scientific research, the 
refinement of study designs, improvements 
in methods of exposure assessment, and the 
use of biomarkers have helped to address the 
problems (e.g., newer studies on the effects 
of air pollution, the growth in opportuni-
ties to examine gene–environment interac-
tions) (Gallo et al. 2011). In some situations, 
there is less of a problem. For example, in 
occupational studies, exposures and relative 
risks may be higher while differences in 
lifestyle factors between different groups of 
workers are smaller (Checkoway et al. 2004); 
thus, any confounding by non occupational 
factors is likely to be weak, even from potent 
causes of cancer such as cigarette smoking 
(Siemiatycki et al. 1988). Of course, the 
interpretation of such studies is enhanced 
when there is supporting evidence from bioas-
says and/or mechanistic studies.
False-positive and false-negative findings 
in individual studies may arise by chance 
or bias, including bias due to confounding 
(Rothman et al. 2008). However, the evalua-
tion of multiple independent epidemiologic 
studies from various geographic locations, 
involving a variety of study designs, as well as 
evidence from experimental studies, reduces 
the possibility that false-positive findings from 
any individual study influences the overall 
evalua tion process. Some studies may have 
greater influence than others because of meth-
odological strengths and/or large sample size. 
The use of information from a variety of study 
designs reduces the likelihood of false-positive 
evaluations because it is unlikely that the same 
biases will occur in multiple studies based on 
different populations under different study 
designs. Moreover, apparently conflicting 
results from epidemiologic studies do not 
necessarily indicate that some are false positive 
or false negative. This might, for example, 
reflect differences in levels of exposure or 
susceptibility to the effects of exposure 
(effect modification). Finally, judgment by 
the Working Group is not based exclusively 
on epidemiologic studies but usually also 
on results from laboratory and mechanistic 
studies that provide further evidence and 
biological coherence. For the Monographs 
that evaluate carcinogenic hazards associated 
with specific occupations or industries, the 
exposures of interest usually involve a complex 
mixture of chemicals. For these evaluations, 
most information comes from epidemiologic 
studies, although exposures to individual 
agents occurring at these workplaces may have 
been evaluated in experi mental studies.
Discontent with IARC Monograph 
processes. The IARC Monograph evalua tion 
process has been criticized and it has been 
alleged that “a number of scientists with 
direct experience of IARC have felt compelled 
to dissociate themselves from the agency’s 
approach to evaluating carcinogenic hazards” 
(Kabat 2012). This is a serious charge. 
However, the author of this claim provided 
no evidence to support the charge that a 
“number of scientists” have dissociated them-
selves from the process, nor has there been 
any indication of how many scientists have 
taken this step, or for what reason. In science, 
we expect sweeping statements such as this to 
be appropriately documented. We have not 
been able to identify any credible support for 
this contention.
There is an IARC Governing Council 
and a Scientific Council to provide oversight 
and guidance to the agency. The Governing 
Council represents the participating states 
and sets general IARC policy. It appoints the 
IARC Director and members of the Scientific 
Council. The latter are independent scientists 
who are selected to provide scientific exper-
tise and not as representatives of the member 
states. They serve for 4 years and serve without 
pay. The voting members of Monograph 
Working Groups are not employed by IARC, 
and they perform this task without financial 
compensation. There have been 111 volumes, 
including six separate documents under 
Volume 100, and three Supplements. Over 
the years, as the number of publications for 
each agent to be evaluated increased, the size 
of Working Groups has increased. Early in the 
process they were sometimes as small as 10, 
but now they sometimes include as many as 
30 scientists. We estimate that over the entire 
Monograph series, approximately 1,500 scien-
tists have served as Working Group members, 
and of course many scientists have also served 
on the Advisory Groups, Scientific Council, 
and Governing Council. Thus, if even a small 
percentage of these scientists were disen-
chanted with the IARC process, it would result 
in a considerable number of such individuals 
and should be easy to document. To be taken 
seriously, the “dissociation” criticism needs 
to be supported by documented information 
describing the number of scientists who have 
taken this action.
Criticisms of specific evaluations. Some 
criticisms of the IARC process relate to 
specific agents, where it is asserted that the 
hazard evaluations of category 2B, 2A, or 1 
are not supported by the scientific literature. 
In the 111 volumes of the Monographs 
produced over the four decades since 1971, 
970 agents have been considered, 114 
(12%) have been classified as carcinogenic 
to humans (Group 1), 69 (7%) as probably 
carcinogenic (Group 2A), 283 (29%) as 
possibly carcinogenic (Group 2B), 504 (52%) 
as not classifiable regarding their carcinoge-
nicity (Group 3), and 1 (< 1%) as probably 
not carcinogenic to humans (Group 4). Thus, 
even for this highly select group of agents 
(i.e., those selected for evalua tion because 
there was some concern that they might be 
carcinogenic), more than one-half were “not 
classifiable” or “probably not carcino genic,” 
and a further 29% were placed into the 
category of possibly carcinogenic to humans. 
This distribution, based on nearly 1,000 eval-
uations in which fewer than one in five agents 
were classified as carcinogenic or probably 
carcinogenic to humans, does not support a 
conclusion that the process is heavily biased 
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toward classifying agents as carcinogenic 
(Boffetta et al. 2009; Kabat 2012).
The monographs for formaldehyde, coffee, 
DDT, and radiofrequency electro magnetic 
radiation have been cited as examples of prob-
lematic evaluations by some (Kabat 2012) 
[among these, only formaldehyde was classi-
fied as known to be carcinogenic to humans 
(Group 1) by an IARC Working Group]. 
These are important agents. However, to 
accept the charge that IARC evaluations are 
fundamentally biased, one has to assume 
that the scientists who were members of the 
Working Groups were incapable of appro-
priately evaluating weaknesses in the data, 
or that they distorted the evaluative process 
because of personal biases. In our experience, 
neither of these assertions is correct. Dissent 
among scientists is not unusual in any area 
of science. It is a strength of the scientific 
process. The IARC process capitalizes on this 
by bringing scientists from different disci-
plines together in one room to evaluate the 
literature and to reach a reasoned conclusion. 
Differences of opinion occur among Working 
Group members. These differences, however, 
typically involve disputes related to assign-
ment to adjacent classification categories. It is 
instructive that there are no instances in which 
a carcinogen classified at the Group 1 level 
by one Working Group has been reversed 
by another. The recent review of all Group 1 
agents for Volume 100 provided ample oppor-
tunity to reverse such previous classifications, 
but none occurred. Every scientist could 
probably name a substance that has been 
reviewed by IARC that they might person-
ally place in a different category from that 
assigned by the Working Group, but this is 
one opinion against the collective wisdom and 
process of the Working Group.
Criticisms of the composition of the 
working groups. The composition of the 
Working Groups has also been criticized 
(Erren 2011; McLaughlin et al. 2010, 
2011); it has been argued that members of 
the Working Groups who have conducted 
research on the agents under evaluation have 
a vested interest in advancing their own 
research results in the deliberations. This criti-
cism has been addressed directly by Wild and 
colleagues (Wild and Cogliano 2011; Wild 
and Straif 2011) from IARC, and we know 
of no evidence to support this contention. 
Even if some scientists on the Working Group 
have performed research on some of the agents 
being considered, they make up a minority of 
the Working Group because several agents are 
usually evaluated in a single meeting, so the 
number of Working Group members who 
have conducted research on any one agent 
is typically small. Our experience has been 
that having some scientists who are knowl-
edgeable about the studies of the agent under 
evaluation (and can therefore answer technical 
queries) and others from different, but related, 
fields provides a knowledgeable and balanced 
mix of scientific backgrounds for a thoughtful 
evaluation of the literature.
Working Group members do not receive 
any fee for their work, but they are paid travel 
expenses, and there is some prestige associ-
ated with service on an IARC Monograph. 
However, most scientists asked to serve on 
IARC Working Groups have already achieved 
some measure of scientific stature, and there 
is no reason why this should bias their evalua-
tion in one direction or the other. In addition, 
Appendix 1: Classification Categories for the Overall Evaluation 
for the IARC Monographs (IARC 2006) 
Group 1: The agent is carcinogenic to humans.
This category is used when there is sufficient evidence of carcinogenicity in humans. 
Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in 
humans is less than sufficient but there is sufficient evidence of carcinogenicity in experi-
mental animals and strong evidence in exposed humans that the agent acts through a relevant 
mechanism of carcinogenicity.
Group 2.
This category includes agents for which, at one extreme, the degree of evidence of carcino-
genicity in humans is almost sufficient, as well as those for which, at the other extreme, there 
are no human data but for which there is evidence of carcinogenicity in experimental animals. 
Agents are assigned to either Group 2A (probably carcinogenic to humans) or Group 2B 
(possibly carcinogenic to humans) on the basis of epidemiological and experimental evidence 
of carcinogenicity and mechanistic and other relevant data. The terms probably carcinogenic 
and possibly carcinogenic have no quantitative significance and are used simply as descriptors 
of different levels of evidence of human carcinogenicity, with probably carcino genic signifying a 
higher level of evidence than possibly carcinogenic.
Group 2A: The agent is probably carcinogenic to humans.
This category is used when there is limited evidence of carcinogenicity in humans and sufficient 
evidence of carcinogenicity in experimental animals. In some cases, an agent may be classified 
in this category when there is inadequate evidence of carcinogenicity in humans and sufficient 
evidence of carcinogenicity in experimental animals and strong evidence that the carcino-
genesis is mediated by a mechanism that also operates in humans. Exceptionally, an agent 
may be classified in this category solely on the basis of limited evidence of carcinogenicity in 
humans. An agent may be assigned to this category if it clearly belongs, based on mechanistic 
considerations, to a class of agents for which one or more members have been classified in 
Group 1 or Group 2A.
Group 2B: The agent is possibly carcinogenic to humans.
This category is used for agents for which there is limited evidence of carcinogenicity in humans 
and less than sufficient evidence of carcinogenicity in experimental animals. It may also be used 
when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence 
of carcinogenicity in experimental animals. In some instances, an agent for which there is 
inadequate evidence of carcinogenicity in humans and less than sufficient evidence of carcino­
genicity in experimental animals together with supporting evidence from mechanistic and 
other relevant data may be placed in this group. An agent may be classified in this category 
solely on the basis of strong evidence from mechanistic and other relevant data.
Group 3: The agent is not classifiable as to its carcinogenicity to humans.
This category is used most commonly for agents for which the evidence of carcinogenicity is 
inadequate in humans and inadequate or limited in experimental animals.
Exceptionally, agents for which the evidence of carcinogenicity is inadequate in humans 
but sufficient in experimental animals may be placed in this category when there is 
strong evidence that the mechanism of carcinogenicity in experimental animals does not 
operate in humans.
Agents that do not fall into any other group are also placed in this category.
An evaluation in Group 3 is not a determination of non carcinogenicity or overall safety. 
It often means that further research is needed, especially when exposures are widespread or 
the cancer data are consistent with differing interpretations.
Group 4: The agent is probably not carcinogenic to humans.
This category is used for agents for which there is evidence suggesting lack of carcinogenicity in 
humans and in experimental animals. In some instances, agents for which there is inadequate 
evidence of carcinogenicity in humans but evidence suggesting lack of carcinogenicity in experi-
mental animals, consistently and strongly supported by a broad range of mechanistic and 
other relevant data, may be classified in this group.
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IARC strictly requires that any conflict of 
interests be divulged, and does not allow those 
with conflicts of interest to serve on Working 
Groups, although non voting observers who 
may have conflicts of interest are able to attend 
the Working Group meetings.
Conclusions
For more than four decades the IARC 
Monograph Programme has provided evalua-
tions of cancer hazards to humans from many 
different exposures and agents. These are often 
the first evaluations of new and emerging 
threats to public health and, consequently, 
are subject to intense scrutiny. Although these 
evaluations are widely respected and used by 
many organizations, institutions, companies, 
and government agencies to improve the 
public’s health, IARC has recently been subject 
to criticism over conclusions on specific agents, 
the process that leads to such conclusions, 
and membership of the Working Groups. 
Debate and criticism facilitate self-correction 
and a check on the validity in science. We 
are concerned, however, that the criticisms 
expressed by a vocal minority regarding the 
evaluations of a few agents may promote the 
denigration of a process that has served the 
public and public health well for many decades 
for reasons that are not supported by data.
There has been very broad involvement 
of the scientific community in the IARC 
Monograph Programme through partici-
pation in the Working Groups and service 
on the IARC Governing and Scientific 
Councils and ad hoc Advisory Board for 
the Monograph Programme. The long list 
of scientists who are coauthors of this paper 
attests to the strong support that IARC has 
in the scientific community. Many exposures 
that IARC has evaluated have also been 
independently evaluated by other institu-
tions, such as the U.S. National Toxicology 
Program (https://ntp.niehs.nih.gov/); U.S. 
Environmental Protection Agency (http://
www.epa.gov/); National Academy of 
Sciences (http://www.nasonline.org/); the 
American Conference of Governmental 
Industrial Hygienists (ACGIH) Threshold 
Limit Values and Biological Exposure Indices 
(http://www.acgih.org/); the Nordic Expert 
Group for Criteria Documentation of 
Health Risks from Chemicals (http://www.
av.se/arkiv/neg/); Institute of Occupational 
Medicine (http://www.iom-world.org/); 
World Cancer Research Fund/American 
Institute for Cancer Research (WCRF/
AICR) Expert Reports; European Chemicals 
Agency (https://echa.europa.eu); Swedish 
Criteria Group for Occupational Standards 
(2013); California Office of Environmental 
Hazard Assessment (Proposition 65; http://
oehha.ca.gov/prop65/background/p65plain.
html); Health Canada Bureau of Chemical 
Safety (http://www.hc-sc.gc.ca/ahc-asc/
branch-dirgen/hpfb-dgpsa/fd-da/bcs-bsc/
index-eng.php); Scientific Committee on 
Occupational Exposure Limits (SCOEL), 
European Commission, Employment, Social 
Affairs and Inclusion (http://ec.europa.eu/
social/main.jsp?catId=148&langId=en&intPa
geId=684); European Food Safety Authority 
(EFSA 2013); and European Chemicals 
Agency (ECHA; http://echa.europa.eu/). 
Assessments from these groups typically come 
to conclusions similar to those from IARC. 
This further indicates broad agreement within 
the scientific community regarding evidence 
on carcino genicity in the scientific literature 
and expands the number of scientists who 
do not have a “vested interest” but who have 
generally agreed with those conclusions.
Disagreement with the conclusions in an 
IARC Monograph for an individual agent is 
not evidence for a failed or biased approach. 
Some disagreement about the carcinogenic 
hazard of important agents seems inherent to 
the scientific enterprise and is unavoidable at 
early stages of the hazard evaluation, where 
IARC usually operates. Because the evalua-
tions are not—and should not be—static, it 
is difficult to see how such assessments could 
be addressed any differently. Substances now 
universally recognized as human carcinogens 
(e.g., tobacco, asbestos) at one time went 
through a quite lengthy period of contentious 
debate (Michaels 2006, 2008). Any process 
can in theory be improved with fair and 
constructive criticism; appropriate reviews may 
take place from time to time, and we would 
support continued review and improvement 
of the IARC processes. However, as a group of 
international scientists, we have looked care-
fully at the recent charges of flaws and bias 
in the hazard evaluations by IARC Working 
Groups, and we have concluded that the recent 
criticisms are unfair and unconstructive.
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